{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:17:02Z","timestamp":1792005422930,"version":"4.4.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Merck Investigator Studies Program"},{"name":"Merck and Co. Inc."},{"name":"National Institutes of Health UNC Center for AIDS Research","award":["P30 AI50410"],"award-info":[{"award-number":["P30 AI50410"]}],"id":[{"id":"https:\/\/ror.org\/05n52x113","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Physiological changes during pregnancy may alter the pharmacokinetics of antiretrovirals, but pregnancy pharmacokinetic\/dynamic data may lag years after drug approval. This single-dose approach allows for earlier data generation, estimating total and protein-unbound doravirine pharmacokinetics in women with human immunodeficiency virus during their second trimester, third trimester, and postpartum.<\/jats:p>\n                  <jats:p>Pregnancy may alter pharmacokinetics of antiretrovirals, but pharmacokinetic\/dosing recommendations can lag years after drug approval. Our approach, measuring single-dose (and estimating steady-state) total and protein-unbound doravirine pharmacokinetics in pregnant women with human immunodeficiency virus, can safely generate early data.<\/jats:p>","DOI":"10.1093\/infdis\/jiag484","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:31:14Z","timestamp":1790335874000},"source":"Crossref","is-referenced-by-count":1,"title":["Changes in Doravirine Pharmacokinetics During Pregnancy: A Longitudinal Single-Dose Study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0150-0500","authenticated-orcid":false,"given":"Amanda","family":"Poliseno","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rahangdale","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Schauer","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sykes","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3620-3059","authenticated-orcid":false,"given":"Cynthia","family":"Gay","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Trawick","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-8493","authenticated-orcid":false,"given":"Angela D M","family":"Kashuba","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026101306414185100_jiag484-B1","author":"World Health Organization"},{"key":"2026101306414185100_jiag484-B2","author":"Department of Health and Human Services"},{"key":"2026101306414185100_jiag484-B3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/pharmaceutics17070913","article-title":"Pharmacokinetic adaptations in pregnancy: implications for optimizing antiretroviral therapy in HIV-positive women","volume":"17","author":"Brice\u00f1o-Pati\u00f1o","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026101306414185100_jiag484-B4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ogc.2022.10.013","article-title":"Antiretrovirals for human immunodeficiency virus treatment and prevention in pregnancy","volume":"50","author":"Brooks","year":"2023","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2026101306414185100_jiag484-B5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cid\/ciz121","article-title":"Importance of prospective studies in pregnant and breastfeeding women living with human immunodeficiency virus","volume":"69","author":"Colbers","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026101306414185100_jiag484-B6","doi-asserted-by":"crossref","first-page":"e25846","DOI":"10.1002\/jia2.25846","article-title":"Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project","volume":"24","author":"Lyerly","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2026101306414185100_jiag484-B7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40262-022-01127-0","article-title":"Prediction of maternal and fetal doravirine exposure by integrating physiologically based pharmacokinetic modeling and human placenta perfusion experiments","volume":"61","author":"Bukkems","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026101306414185100_jiag484-B8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","article-title":"Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?","volume":"41","author":"Isoherranen","year":"2013","journal-title":"Drug Metabol Dispos"},{"key":"2026101306414185100_jiag484-B9","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/jac\/dkab202","article-title":"Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model","volume":"76","author":"L\u00ea","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026101306414185100_jiag484-B10","doi-asserted-by":"crossref","first-page":"e89990","DOI":"10.2196\/89990","article-title":"Single-dose longitudinal pharmacokinetic evaluation of doravirine in pregnant women living with HIV: protocol for a phase 1 study","volume":"15","author":"Poliseno","year":"2026","journal-title":"JMIR Res Protoc"},{"key":"2026101306414185100_jiag484-B11","doi-asserted-by":"crossref","first-page":"e70134","DOI":"10.1002\/jcph.70134","article-title":"Population pharmacokinetics of bictegravir during pregnancy and postpartum: role of adherence in maintaining therapeutic exposure","volume":"66","author":"Sun","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"2026101306414185100_jiag484-B12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAI.0b013e31827fd47e","article-title":"Protein binding of lopinavir and ritonavir during 4 phases of pregnancy","volume":"63","author":"Patterson","year":"2013","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"2026101306414185100_jiag484-B13","doi-asserted-by":"crossref","first-page":"ofaf649","DOI":"10.1093\/ofid\/ofaf649","article-title":"Long-acting cabotegravir\/rilpivirine for treatment of HIV during pregnancy: a case series","volume":"12","author":"Sunagawa","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026101306414185100_jiag484-B14","doi-asserted-by":"crossref","first-page":"e02502-18","DOI":"10.1128\/AAC.02502-18","article-title":"Population pharmacokinetics of doravirine and exposure-response analysis in individuals with HIV-1","volume":"63","author":"Yee","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101306414185100_jiag484-B15","author":"Jennings"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag484\/71403441\/jiag484.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag484\/71403441\/jiag484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:41:50Z","timestamp":1791888110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag484\/8836682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag484","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"article-number":"jiag484"}}